SCHEMBL5607986

SCHEMBL5607986

CCn1c(N=CN(C)c2ccccc2C)cc(=O)n(CC2CC2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.34
CNR2 P34972 3/20 0.33
GRIN2A Q12879 3/20 0.33
GRIA2 P42262 2/20 0.33
PDE5A O76074 2/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
CRHR1 P34998 2/20 0.33
CRHR2 Q13324 2/20 0.33
ALDH1A1 P00352 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PTGER4 P35408 1/20 0.31
BRD4 O60885 1/20 0.31
BAZ2A Q9UIF9 1/20 0.31
PARG Q86W56 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546570 0.82 PDE5A (0.46) LMNASMN1; SMN2HPGDGRIN2AGRIA2
SCHEMBL1546537 0.69 LMNA (0.51) LMNASMN1; SMN2HPGDGRIN2AGRIA2
SCHEMBL2333544 0.69 LMNA (0.52) LMNASMN1; SMN2HPGDPDE5APDE4A
SCHEMBL240142 0.65 LMNA (0.51) LMNASMN1; SMN2HPGDPDE4APDE4B
SCHEMBL2756837 0.65 LMNA (0.51) LMNASMN1; SMN2HPGDPDE4APDE4B
SCHEMBL1546588 0.64 ALDH1A1 (0.50) LMNASMN1; SMN2GRIN2AGRIA2PDE5A
SCHEMBL4639746 0.63 LMNA (0.49) LMNASMN1; SMN2HPGDCNR2PDE4A
SCHEMBL1546128 0.63 LMNA (0.46) LMNASMN1; SMN2HPGDALDH1A1L3MBTL1
SCHEMBL17434511 0.63 NOTUM (0.50) LMNASMN1; SMN2GRIN2AGRIA2PDE5A
SCHEMBL2543060 0.63 LMNA (0.45) LMNASMN1; SMN2HPGDALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799221-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-06-27 EP disclosed
WO-2006044610-A1 METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC (US) 2006-04-27 WO disclosed